Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 24 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 24 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Department of Neurosurgery, Thriassio General Hospital, Athens, Greece

2. Laboratory of Pharmacology, Medical School, University of Athens, Greece

pharmakonpress[at]pharmakonpress[.]gr

2.        Hall E.D.: Beneficial effects of the 21-aminosteroid U-74006F in acute CNS trauma and hypovolemic shock. Acta Anaesthesiol. Belg. 38: 421-425 (1987)

3.        Anderson D.K., Braughler J.M., Hall E.D. et al.: Effects of treatment with U-74006F on neurological Outcome following experimental spinal cord injury. J. Neurosurgery 69: 562-567 (1988)

4.        Kavanagh R.J., Kam P.C.A.: Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br. J. Anaesth. 86: 110-119 (2001)

5.        Gilgun-Sherki Y., Rosenbaum Z., Melamed E., et al.: Antioxidant therapy in acute central nervous system injury: current state. Pharmacol. Rev. 54: 271-284 (2002)

6.        Halliwell B., Gutteridge J.M.C.: Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219: 1-14 (1984)

7.         Warner D.S., Sheng H., Batinic-Haberle I.: Oxidants, antioxidants and the ischemic brain. Exp. Biol. 207: 3221-3231 (2004)

8.        Hall E.D., Yonkers P.A., Andrus P.K. et al.: Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J. Neurotrauma 9(Suppl. 2): 425-442 (1992)

9.        Hi nzmann J.S., McKenna R.L., Pierson T.S.: Interaction of antioxidants with depth-dependent fluorescence quenchers and energy transfer probes in lipid bilayers. Chem. Phys. Lipids 62: 123-138 (1992)

10.      Altav lla D., Squadrito F., Serano M., et al: Inhibition of tumour necrosis factor and reversal of endotoxin- induced shock by U-83836E, a second generation lazaroid in rats. Br. J. Pharmacol. 124: 1293-1299 (1998)

11.       Kabadere S., Oztopcu P., Korkmaz S., et al: MgSO₄ and lazaroid U- 83836E partially protects glioma cells against glutamate toxicity in vitro. Acta Neurobiol. Exp. 64: 461-466 (2004)

12.      Durmaz R., Deliorman S., Isksoy S., et al: Antiproliferative properties of the Lazaroids U-83836E and U-74389G on glioma cells in vitro. Pathol. Oncol. Res. 5: 223-228 (1999)

13.      Jacobsen E.J., McCall J.M., Ayer D.E., et al.: Novel 21-aminosteroids that inhibit iron-dependent lipid peroxidation and protect against central nervous system trauma. J. Med. Chem. 33: 1145-1151 (1990)

14.      Hall E.D.: Effects of the 21-aminosteroid U-74006F on posttraumatic spinal cord ischemia in cats. J. Neurosurgery 68: 462-465 (1988)

15.      Park C.K., Hall E.D.: Dose-response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia. Brain Res. 645: 157-163 (1994)

16.      Maruki Y., Koehler R.C., Kirsch J.R., et al.: Effect of the 21-aminosteroid tirilazad on cerebral pH and somatosensory evoked potentials after incomplete ischemia. Stroke 24: 724-730 (1993)

17.       Zuccarello M., Marsch J.T., Schmitt G., et al.: Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. J. Neurosurgery 71: 98-104 (1989)

18.      Zuccarello M., Anderson D.K.: Interaction between free radicals and excitatory aminoacids in the blood-brain barrier disruption after iron injury in the rat. J. Neurotrauma 10: 397-403 (1993)

19.      Marshall L.F., Maas R.C., Marshall S.B., et al.: A multicentre trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurgery 89: 519-525 (1998)

20.      Bracken M.B., Shephard M.J., Holford T.R., et al.: Administration of methylprednisolone for 24 or 48h or tirilazad mesylate for 48h in the treatment of acute spinal cord injury: results of the third national acute spinal cord injury randomized controlled trial. JAMA 277: 1597-1604 (1997)

21.      The Ranttas II Investigators: High dose tirilazad mesylate in patients with acute stroke. Stroke 29: 1256-1257 (1998)

22.      Kassell N.F., Haley E.C., Apperson-Hansen C., et al.: Randomised, double-blind, vehicle controlled trial of tirilazad mesylate in patients with aneurismal subarachnoid haemorrhage: a cooperative study in Europe, Australia and New Zealand. J Neurosurgery 84: 221-228 (1996)

23.      Lanzino G., Kassell N.F., Dorsch N.W.: Randomised, double-blind, vehicle controlled study of high dose tirilazad mesylate in women with aneurysmal subarachnoid haemorrhage. Part I. Acooperative study i n Europe, Australia, New Zealand and South Africa. J. Neurosurgery 90: 1011-1117 (1999)

24.      Lanzino G., Kassell N.F., Dorsch N.W.: Randomised, double-blind, vehicle controlled study of high dose tirilazad mesylate in women with aneurysmal subarachnoid haemorrhage. Part II. A cooperative study in Europe, Australia New Zealand and South Africa. J. Neurosurgery 90: 1018-1024 (1999)

25.      Lucas S.-M., Rothwell N.J., G i bson R.: M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 147: S232-S240 (2006)

26.      Hall E.D., Springer J.E.: Neuroprotection and acute spinal cord injury: A reappraisal. J. Am. Soc. Exp. Neurother. 1: 80-100 (2004)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr